In recent years, many studies demonstrated that MMR deficiency and MSI, similarly to TMB, could predict the tumor response to immunotherapies consisting of the administration of anti-PD-1 (pembrolizumab and nivolumab) and anti-PD-L1 (atezolizumab and durvalumab) antibodies. Here, PDCD1 is linked to neoplasm.